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Introduction
New Cross-Bridged Cyclen Ligands and Their Transition Metal Complexes as CXCR4 Antagonists
ili Ashlie Walker1. Megan Ayala1. Justin G. Le1, Dr. Timothy J. Hubin1
*  1. Department of Chemistry, Southwestern Oklahoma State University, 100 Campus Drive, Weatherford, OK 73096
Synthesis and Characterization of the Propyl Cross-Bridged Ligands
Methods: Synthetic routes extending our bis-linked ligand syntheses to synthesize and link a 
propyl cross-bridged cyclen were developed. The propyl cross-bridged cyclen is a challenging 
synthesis with rather low yields. Linking two of these macrocycles with a xylene group is the 
next step planned.1. CXCR4 is a co-receptor on the surface of immune cells that has 
been proven to facilitate the entry of HIV into the cells. (fig 1)
Within the last 15 years the 
CXCR4 and CCR5 co­
receptors have influenced new 
therapeutic approaches to the 
treatment of HIV via fusion 
inhibitor drugs that target these 
receptors.
Our aim is to develop new 
antagonists for the CXCR4 co­
receptor. Specifically, the goal 
was the synthesis of Propyl 
Cross-Bridged, linked 
analogues of the known 
CXCR4 antagonist AMD-3100.
2. AMD 3100 is a known CXCR4 
binding fusion inhibitor. Each 
macrocycle can bind to metal ions 
giving rise to six possible 
configurations. (fig 2)
3. Previously synthesized 
Ethylene Cross-Bridged 
analogues have proven to be 
even more potent antagonists 
than AMD3100. A potential 
problem with these complexes is 
stability. The Propyl Cross­
Bridged versions may be more 
stable.
Synthesis and Characterization of the Transition Metal Complexes
Conclusion
Propyl Cross-Bridged bis-linked bridged tetraazamacrocycles are difficult, but 
possible to produce. Metal ion complexation with single-macrocycle analogues 
proceeds smoothly following known procedures. The resulting complexes will inform 
our understanding of the requirements for producing even more efficient CXCR4 
antagonists of this class. Chemical characterization of the complexes produced 
need to be completed prior to complexation with the bis-linked analogues and 
biological testing of the CXCR4 binding ability of these new compounds. Results: The ligand syntheses of the Propyl Cross-Bridged ligands proceeded 
similarly to the previously developed bis-ligand routes. Complexation with desired 
metal ions for single-macrocycle analogues proceeded as expected.
E le m e n t a l  A n a l y s e s  o f  B n 2P B C y c l e n  C o m p le x e s
% C % H  1 % N
rM n (C 2 5 H 3RN 4 )(C H 3 O 2 )] [P F 6 • I . 9 N H 4P F 6
C a lc u la te d 3 3 . 7 4 4 . 8 9 8 . 6 0
F o u n d 3 3 . 5 8 5 . 0 3 8 . 3 9
[F e (C 25 H 36 N 4 )(C 2H 3O 2 )][P F6 ] • 1 .2 N H 4P F 6
C a lc u la te d 3 8 .2 4 5 .2 1 8 .5 9
F o u n d 3 8 .3 2 5 .1 4 8 .5 9
[C o (C 25H 36N 4)(C 2 H 3O 2 )][P F6 ]
C a lc u la te d 4 9 .4 7 6 .0 0 8 .5 5
F o u n d 4 9 .7 7 6 .1 2 9 .2 5
[N i(C 25H 36N 4 )(C 2H 3O 2 )][P F6 ] • 0 . 1 N H 4P F 6
C a lc u la te d 4 8 .2 9 5 .9 1 8 .5 5
F o u n d 4 8 . 2 6 6 . 0 4 8 . 9 6
[C u (C 2 5 H 36N 4)(C 2 H 3O 2)q.38] [P F 6] 1.62
C a lc u la te d 4 3 .3 7 5 .2 5 7 .8 5
F o u n d 4 3 .1 2 5 .4 2 8 .2 5
[Zn (C 2 5H 36N 4 )(C 2H 3O 2 )][P F6 ]
C a lc u la te d 4 8 .9 9 5 .9 4 8 .4 6
F o u n d 4 8 .0 8 5 .7 8 8 .9 5Acknowledgements
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